Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. MYND Lifesciencs Inc.
  6. News
  7. Summary
    MYND   CA62857B1094

MYND LIFESCIENCS INC.

(MYND)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MYND Life Sciences Inc :. Announces RSU Grant

09/29/2021 | 06:51am EST

VANCOUVER, BC, Sept. 29, 2021 /CNW/ - MYND Life Sciences Inc. ("MYND" or the "Company"), has granted an aggregate of 234,192 restricted share units (the "RSUs") to officers and employees pursuant to the Company's RSU plan.

The Company's RSU and stock-based option plans are aimed to compensate and reward its directors, officers and employees for working towards the Company's long-term objectives and in alignment with the shareholders' best interest.

ABOUT MYND LIFE SCIENCES

MYND Life Science Inc. is a leading life sciences company focused on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through exemptions granted to its Chief Science Officer, Dr. Wilfred Jefferies. Four separate patents have been filed based on Dr. Jefferies' very promising research and development that commenced in 2010 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development is currently being performed.

CONTACT INFORMATION
CEO Dr. Lyle Oberg
Email: IR@myndlifesciences.com 
Web: www.myndlifesciences.com

Forward-Looking Information
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. The forward-looking statements herein are made as of the date of this press release only, and the Company does not assume any obligation to update or revise them to reflect new information, estimates or opinions, future events, or results or otherwise, except as required by applicable law. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budgets", "scheduled", "estimates", "forecasts", "predicts", "projects", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this press release includes, long-term objectives, and management's expectations regarding MYND's growth. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of MYND to control or predict, that may cause MYND's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including, but not limited to, the risk factors set out under the heading "Risk Factors" in the Company's final non-offering long form prospectus dated May 12, 2021 available for review on the Company's profile at www.sedar.com. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/mynd-life-sciences-inc-announces-rsu-grant-301387674.html

SOURCE Mynd Life Sciences Inc.

© Canada Newswire, source Canada Newswire English

All news about MYND LIFESCIENCS INC.
11/30MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation
AQ
11/18MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test
AQ
11/18MYND Diagnostics Inc. Commences Clinical Research on Multiple Sclerosis Biomarker Test
CI
10/28MYND Lifesciencs Inc. Announces Board and Audit Committee Changes
CI
10/27MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Tre..
CI
10/18KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Vie..
AQ
10/11KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
AQ
10/07MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidi..
CI
09/29MYND LIFE SCIENCES INC : . Announces RSU Grant
AQ
09/09MYND Lifesciencs Inc. announced that it has received CAD 2.7 million in funding
CI
More news
Financials
Sales 2020 - - -
Net income 2020 -0,00 M -0,00 M -0,00 M
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 11,3 M 8,94 M 8,94 M
Capi. / Sales 2019 -
Capi. / Sales 2020 -
Nbr of Employees 10
Free-Float -
Chart MYND LIFESCIENCS INC.
Duration : Period :
MYND Lifesciencs Inc. Technical Analysis Chart | MYND | CA62857B1094 | MarketScreener
Income Statement Evolution
Managers and Directors
Lyle Oberg Chief Executive Officer & Director
Paul Ciullo Chief Financial Officer & Secretary
Wilfred A. Jefferies Chairman & Chief Science Officer
Jordan Cleland Chief Operating Officer
John Campbell Independent Director